Dublin, Ireland--(Marketwire - March 18, 2008) -
AGI Therapeutics PLC
Notification of Results
AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality
pharmaceutical company focused on gastrointestinal drug products, will be
announcing its preliminary results for the year ended 31 December 2007 on
Thursday, 3 April 2008.
An analyst briefing will be held at 09.30am on 3 April 2008 at the offices of Piper Jaffray, One South Place, London EC2M 2RB.
Contact Information:
AGI Therapeutics plc. Tel: +353 1 449 3254
David Kelly, Chief Financial Officer
Financial Dynamics - UK Tel: +44 (0) 20 7269 7182
Deborah Scott/Lara Mott
Financial Dynamics - Ireland Tel: +353 1 663 3607
Aisling Garvey
Piper Jaffray Limited Tel: +44 (0) 20 3142 8700
Neil Mackison
Will Carnwath
Davy Tel: +353 (1) 614 8761
John Frain
Notes to Editors:
About AGI Therapeutics plc
AGI is a speciality pharmaceutical company which is focused on the development
and commercialisation of differentiated drug products for gastrointestinal (GI)
diseases and disorders. AGI's common shares are listed on the Alternative
Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise
Exchange of the Irish Stock Market (IEX) as AGI.
The Company has a portfolio of product candidates derived from its Known
Molecular Entity (KME) approach to drug re-profiling and development. The
Company's lead product candidate, Rezular, is an orally administered
triple-action intestinal regulator, a first-in-class mechanism for the treatment
of Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D). Rezular is
currently in Phase III clinical trials.
KME is a re-profiling methodology used by the Company to identify existing
therapeutic drugs which typically have been marketed for a number of years, have
established safety profiles and can be developed for new clinical indications or
with improved profiles in their existing clinical indications. In this way, the
Company seeks to reduce the risk, time and cost of new product development as
compared to the development of new chemical entities.
AGI is developing a range of product candidates to treat a variety of prevalent
GI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia,
gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and
diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The
Company is targeting areas of the GI therapeutic drug products market for its
product candidates where there are currently unmet medical needs or where the
effectiveness of existing drug therapies can be further improved.
The Company has five active clinical stage product candidates which are either
isomers or new drug delivery formulations of existing approved drugs, and which
have established safety and tolerability profiles in their currently approved
clinical indications.
For further information please see
www.agitherapeutics.com
This information is provided by RNS
The company news service from the London Stock Exchange